News

NousQ was voted the winner of the 2022 Asia Pacific Accelerator program

  Posted 19 October NousQ was voted the winner of the 2022 Asia Pacific Accelerator program with a US$175,000 non-dilutive grand prize, as determined by a live audience vote on 26 September during the MedTech Innovator Asia Pacific…

AndHealth CEO Bronwyn Le Grice Recipient of 2022 Telstra Health Brilliant Woman in Digital Health Award

ANDHealth is proud to announce that CEO and Managing Director, Bronwyn Le Grice, has been recognised in the 2022 Brilliant Women in Digital Health Awards as one of 25 women honoured for outstanding achievements and contributions in digital…

AdAlta and GPCR Therapeutics collaborate on novel cancer

          Posted: 14 October AdAlta Limited, the clinical stage drug discovery company developing novel therapeutic products from its i-body platform and GPCR Therapeutics Inc, a clinical stage biotech company discovering and developing innovative therapeutics…

Cartherics granted first US patent for multiple development candidates

Posted: 7 October Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced that it has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”. This patent provides a proprietary position…

Refer a student for this special rate

Posted: 7 October Help a university student you know accelerate their studies with essential insight from Australia’s leading business newsroom for $5 per week. What’s included? Unlimited afr.com website access Financial Review iPhone and iPad app Curated daily…

Future You is live!

Future You, an initiative from the Australian Government’s Women in STEM Ambassador, Professor Lisa Harvey-Smith, has launched its Pathfinders series to help children aged 8 to 12 understand and explore pathways to exciting and rewarding STEM careers. The…

Immutep Receives FDA Fast Track Designation for Efti for First Line Non-Small Cell Lung Cancer

Posted: 5 October Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer • Based on the encouraging Phase II clinical data for PD-L1 all-comers…

Optiscan Featured in Health Leader TV 2022

Posted: 4 October Part of the Australasian College of Health Service Management (ACHSM), Health Leader TV is a leading and trusted source of health service management information across the Australasian region. They provide best practice information, cutting-edge research…

Aculeus Therapeutics announces IND-enabling studies to advance lead program ACU-0943 towards clinical trials

Posted: 3 October Aculeus Therapeutics is a life sciences company focused on discovering and developing novel immunotherapies to treat a range of serious diseases. Today, Aculeus announced that it has initiated Investigational New Drug, or IND-enabling, studies for…

New $2.5m genomics project boosts precision medicine

Posted: 27 September The funding from the Medical Research Future Fund (MRFF) Genomics Health Futures Mission will support research to harness the full potential of genomic data to improve diagnosis and inform clinical care for all patients who…

Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers

Posted: 27 September Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy…

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

Posted: 26 September Immutep Limited, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a A$2,693,046 research and development (R&D) tax incentive payment in cash from…

Home

News & opinion

Member Directory

Events